Evidence map›Paper›PMID 35359407›Full record

ArticleFrontiers in oncology2022

Outcomes of Patients With Active Cancer and COVID-19 in the Intensive-Care Unit: A Multicenter Ambispective Study.

Henri Plais, Marie Labruyère, Thibault Creutin, Paula Nay, Gaëtan Plantefeve, Romain Tapponnier, Maud Jonas, Nadege Tchikangoua Ngapmen, Loïc Le Guennec, Charles De Roquetaillade and 12 more

Abstract read
In one paragraph

Article in Frontiers in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Henri PlaisIntensive Care Unit, Gustave Roussy, Université Paris-Saclay, Villejuif, France.
Marie LabruyèreDepartment of Intensive Care, Dijon Bourgogne University Hospital, Dijon, France.
Thibault CreutinService de Médecine Intensive and Réanimation, APHP-CUP, Hôpital Cochin, Paris, France.
Paula NayMedical Intensive Care Unit, Ambroise Paré Hospital, AP-HP, Boulogne-Billancourt, France.
Gaëtan PlantefeveService de Réanimation Polyvalente, Centre Hospitalier Victor Dupouy, Argenteuil, France.
Romain TapponnierMedical Intensive Care Unit, Hôpital Jean Minjoz Hospital, Besançon, France.
Maud JonasCentre Hospitalier Général de Saint-Nazaire, Service de Médecine Intensive Réanimation, Saint-Nazaire, France.
Nadege Tchikangoua NgapmenIntensive Care Unit, Centre Hospitalier de Château-Thierry, Château-Thierry, France.
Loïc Le GuennecMédecine Intensive Réanimation Neurologique, Département de Neurologie, Groupe Hospitalier Pitié-Salpêtrière, Assistance Publique-Hôpitaux de Paris, Paris, France.
Charles De RoquetailladeDepartment of Anesthesiology and Critical Care, Hôpital Lariboisière, FHU PROMICE, DMU Parabol, APHP, Paris, France.
Laurent ArgaudMedical ICU, Edouard Herriot University Hospital, Lyon, France.
Matthieu JammeIntensive Care Unit, Poissy-Saint-Germain-en-Laye Hospital, Poissy, France.
Cyril GoulenokMedical-Surgical Intensive Care Unit, Ramsay Générale de Santé, Hôpital Privé Jacques Cartier, Massy, France.
Karim MerouaniMedical and Surgical Intensive Care Unit, Alençon Hospital, Alençon, France.
Maxime LeclercIntensive Care Unit, Centre Hospitalier Mémorial France Etats-Unis, Saint-Lô, France.
Bertrand SauneufRéanimation - Médecine Intensive, Centre Hospitalier Public du Cotentin, Cherbourg-en-Cotentin, France.
Sami ShidaspIntensive Care Unit, Etampes Hospital, Etampes, France.
Annabelle StoclinIntensive Care Unit, Centre Hospitalier de Château-Thierry, Château-Thierry, France.
Aurélie BardetBureau of Biostatistics and Epidemiology, Gustave Roussy, University Paris-Saclay, Villejuif, France and U1018 INSERM Oncostat, University Paris-Saclay, Labeled Ligue Contre le Cancer, Villejuif, France.
Olivier MirGustave-Roussy, Département d'oncologie Médicale, Villejuif, France.
Nusaibah IbrahimiBureau of Biostatistics and Epidemiology, Gustave Roussy, University Paris-Saclay, Villejuif, France and U1018 INSERM Oncostat, University Paris-Saclay, Labeled Ligue Contre le Cancer, Villejuif, France.
Jean-François LlitjosIntensive Care Unit, Gustave Roussy, Université Paris-Saclay, Villejuif, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Several studies report an increased susceptibility to SARS-CoV-2 infection in cancer patients. However, data in the intensive care unit (ICU) are scarce. Research Question: We aimed to investigate the association between active cancer and mortality among patients requiring organ support in the ICU. Study Design and Methods: In this ambispective study encompassing 17 hospitals in France, we included all adult active cancer patients with SARS-CoV-2 infection requiring organ support and admitted in ICU. For each cancer patient, we included 3 non cancer patients as controls. Patients were matched at the same ratio using the inverse probability weighting approach based on a propensity score assessing the probability of cancer at admission. Mortality at day 60 after ICU admission was compared between cancer patients and non-cancer patients using primary logistic regression analysis and secondary multivariable analyses. Results: Between March 12, 2020 and March 8, 2021, 2608 patients were admitted with SARS-CoV-2 infection in our study, accounting for 2.8% of the total population of patients with SARS-CoV-2 admitted in all French ICUs within the same period. Among them, 105 (n=4%) presented with cancer (51 patients had hematological malignancy and 54 patients had solid tumors). 409 of 420 patients were included in the propensity score matching process, of whom 307 patients in the non-cancer group and 102 patients in the cancer group. 145 patients (35%) died in the ICU at day 60, 59 (56%) with cancer and 86 (27%) without cancer. In the primary logistic regression analysis, the odds ratio for death associated to cancer was 2.3 (95%CI 1.24 - 4.28, p=0.0082) higher for cancer patients than for a non-cancer patient at ICU admission. Exploratory multivariable analyses showed that solid tumor (OR: 2.344 (0.87-6.31), p=0.062) and hematological malignancies (OR: 4.144 (1.24-13.83), p=0.062) were independently associated with mortality. Interpretation: Patients with cancer and requiring ICU admission for SARS-CoV-2 infection had an increased mortality, hematological malignancy harboring the higher risk in comparison to solid tumors.

Indexed as

cancerCOVID-19hematological malignanciesintensive care unitsolid tumors

Identifiers

PMID35359407
PMCPMC8960921

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.